Inference for the cost-effectiveness acceptability curve and cost- effectiveness ratio

PharmacoEconomics

Volumn 17, Issue 4, 2000, Pages 339-349

  O'Hagan, Anthony ^a   Stevens, John W ^b   Montmartin, Jacques ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034010546     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017040-00004     Document Type: Review

References (27)

1. 1. Drummond MF, O'Brien BJ. Clinical importance, statistical significance and the assessment of the economic and quality-of-life outcomes. Health Econ 1993; 2: 205-12
2. 2. Van Hout BA, AJ MJ, Gordon GS, et al. Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994; 3: 309-19
3. 3. O'Brien BJ, Drummond MF. Statistical versus quantitative significance in the socio-economic evaluation of medicines. Pharmacoeconomics 1994; 5: 389-98
4. 4. Wakker P, Klaassen MP. Confidence intervals for cost/effectiveness ratios. Health Econ 1995; 4: 373-81
5. 5. Coyle D. Statistical analysis in pharmacoeconomic studies. Pharmacoeconomics 1996; 9: 506-16
6. 6. Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Econ 1996; 5: 297-305
7. 7. Mason J. The generalisability of pharmacoeconomic studies. Pharmacoeconomics 1997; 11: 503-14
8. 8. Laska EM, Meisner M, Siegel C. Statistical inference for cost-effectiveness ratios. Health Econ 1997; 6: 229-42
9. 9. Tambour M, Zethraeus N, Johannesson M. A note on confidence intervals in cost-effectiveness analysis. Int J Technol Assess Health Care 1998; 14: 67-471
10. 10. Weinstein MC, Seigal JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-8
11. 11. Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998; 7: 723-40
12. 12. Sacristán JA, Day SJ, Navarro O, et al. Use of confidence intervals and sample size calculations in health economic studies. Ann Pharmacother 1995; 29: 719-25
13. 13. Jones DA. A Bayesian approach to the economic evaluation of health care technologies. In: Spiker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia (PA): Lippincott-Raven, 1996: 1189-96
14. 14. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ 1999; 8: 257-61
15. 15. Bala MV, Mauskoff J. The estimation and use of confidence intervals in economic analysis. Drug Inf J 1999; 33: 841-8
16. 16. O'Hagan A, Stevens JW, Montmartin J. Bayesian cost-effectiveness analysis from clinical trial data. Research report 489/99. Department of Probability and Statistics, University of Sheffield, Sheffield: 1999
17. 17. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990; 10: 212-4
18. 18. Stinnett AA, Mulahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical Decis Making 1998; 18 (2 Suppl.): S68-80
19. 19. Heitjan DF. Moskowitz AJ, Whang W. Bayesian estimation of cost-effectiveness ratios from clinical trials. Health Econ 1999; 8: 191-201
20. 20. Löthgren M, Zethraeus N. On the interpretation of cost-effectiveness acceptability curves. Working paper series in economics and finance. Stockholm: Stockholm School of Economics, 1999: no. 323
21. 21. Fisher CJ, Slotman GJ, Opal SM, et al., IL-1ra Sepsis Syndrome Study Group. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994; 22: 12-21
22. 22. Stuart A, Ord JK. Kendall's advanced theory of statistics. Vol. 2. 5th ed. London: Arnold, 1991: example 20.4
23. 23. Buehler RJ, Fedderson AP. Note on a conditional property of Student's t. Ann Math Stat 1963; 34: 1098-100
24. 24. Tambour M, Zethraeus N. Bootstrap confidence intervals for cost-effectiveness ratios: some simulation results. Econ Eval 1998; 7: 143-7
25. 25. Darby SC. A Bayesian approach to parallel line bioassay. Biometrika 1980; 67: 607-12
26. 26. Lee PM. Bayesian statistics: an introduction. 2nd ed. London: Arnold, 1997
27. 27. Heitjan DF, Moskowitz HJ, Whang W. Problems with interval estimates of the incremental cost-effectiveness ratio. Med Decis Making 1999; 19: 9-15